Rezolute创新小分子KLKB1抑制剂RZ402达临床试验主要终点，针对DME
2024年5月24日 · RZ402 是一种选择性口服小分子血浆激肽释放酶抑制剂（KLKB1），用于慢性治疗糖尿病性黄斑水肿（DME）， RZ-402 通过抑制激肽释放酶的形成， 阻断下游缓激肽的产 …
Recent advances in the discovery and development of drugs …
2024年4月26日 · Diabetic macular edema (DME) is another area where PKa inhibitors are being extensively researched. Studies in DME patients have shown that PKa levels in the vitreous …
Plasma Kallikrein Inhibition in Diabetic Macular Edema
2020年9月1日 · Discover the latest findings on diabetic macular edema (DME) treatments, including the potential of a VEGF-independent pathway for preservation and recovery of …
RZ-402 (RZ-402) - 药物靶点：KLKB1_在研适应症：糖尿病性黄斑水 …
Diabetic Macular Edema (DME) Announced positive topline results in May of 2024 from the Phase 2 proof-of-concept study of RZ402 in patients with DME. The study met primary endpoints, …
Rezolute Announces Initiation of Multiple-Ascending Dose Study …
2021年8月10日 · DME is a severe vision-threatening complication of DR characterized by swelling of the retina and thickening of the macula, the part of the eye that is responsible for high …
AAO 2024: Rezolute’s RZ-402 shows promising Phase IIa results in DME …
2024年10月21日 · The kallikrein-kinin system (KKS) is considered to contribute to DME in a VEGF-independent pathway, where the overactivation of plasma kallikrein ensues in …
Pipeline - Rezolute, Inc.
Diabetic Macular Edema (DME) is a severe, systemic, vision-threatening complication of diabetic retinopathy (DR) characterized by swelling of the retina and thickening of the macula, the part …
Nonclinical safety and pharmacology of RZ402, a plasma kallikrein ...
Purpose : Excessive retinal vascular permeability (VP) is the key defining pathology underlying the development of diabetic macular edema (DME). The serine protease plasma kallikrein …
从最新指南看糖尿病黄斑水肿的一线治疗方案-MedSci.cn
2023年3月28日 · DR是糖尿病导致的视网膜微血管损害所引起的一系列病变；糖尿病黄斑水肿（DME）则是由于黄斑区毛细血管渗漏所致的视网膜增厚，主要影响中心视力。 DME是糖尿 …
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary ...
2018年7月25日 · BCX7353 is a potent oral small-molecule inhibitor of plasma kallikrein with a pharmacokinetic and pharmacodynamic profile that may help prevent angioedema attacks.